Mimetogen Pharmaceuticals is a late stage clinical biotechnology company focused on developing the use of synthetic neurotrophin mimetics as a novel approach to treating ocular surface diseases with high unmet medical needs. The underlying technology was developed at McGill University and the Lady Davis Institute for Medical Research in Montreal.
Mimetogen is focused on the development of its lead compound, tavilermide (previously known as MIM-D3) for dry eye disease (DED). The company has an advanced clinical development program, evaluating tavilermide in multi-center Phase 3 clinical studies in the United States, with a clear approval pathway for DED. In addition, the Company has developed novel therapeutic approaches for ophthalmologic degenerative diseases of the retina such as retinitis pigmentosa.
To successfully advance the development of its novel class of neurotrophin mimetics, Mimetogen management team has assembled a world-class group of advisors comprised of renowned experts and clinical development collaborators in the field of ophthalmology, all dedicated to the development of new therapeutic options for eye diseases that to date have only limited or no treatment or cure.